The companies vary in their mission: One is a gene therapy company founded by Vivek Ramaswamy's brother, while another is a ...

The global gene editing market is expected to reach USD 7.59 billion in 2029 from USD 4.66 billion in 2024, at a CAGR of 10.2 ...

The U.S. Food and Drug Administration approved PTC Therapeutics, Inc.'s Kebilidi (eladocagene exuparvovec-tneq) gene therapy for the ...

BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the sale ...

presented to its investors. Passage Bio, Inc. is a clinical-stage genetic medicines company that focuses on developing therapies to treat neurodegenerative diseases, particularly through gene therapy ...

Operator Good morning and welcome to Ocugen's third quarter 2024 financial results and business update. [Operator ...

The foundation also celebrated in September the opening of a FOXG1 research center at the University of Buffalo, and Zeitzer ...

The ROS-1 NSCLC current market is mainly dominated by tyrosine kinase inhibitors such as XALKORI at present and is anticipated to be dominated ...

HuidaGene Therapeutics ("HuidaGene"), a global clinical-stage biotechnology company, announced that the U.S. FDA has cleared its investigational new drug (IND) application for HG202, the world's first ...

Purespring’s gene therapy, PS-002, uses a viral vector to target kidney cells—known as podocytes—to treat IgA nephropathy, a disease that causes pain, bloody urine and fatigue, and can lead ...